Dr Reddy’s to distribute Takeda’s Qdenga dengue vaccine in India
Dr Reddy’s Laboratories has signed an agreement with Takeda Pharmaceutical to promote and distribute Qdenga in India. The two-dose dengue vaccine is expected to be available in the first half of 2027.
What happened
Dr. Reddy’s Laboratories · Dr Reddy’s signed a deal with Takeda to promote and distribute Qdenga dengue vaccine in India. The regulator-approved two-dose
Key facts
- Qdenga expected in India in first half of 2027
- Two 0.5 ml doses administered three months apart
- India recorded 232,425 dengue cases and 233 deaths in 2024
Why this matters
The deal signals Dr Reddy’s appeal as an India commercialization partner for multinational specialty vaccines, potentially strengthening its case for further in-licensing alliances.
What to watch
- Indian regulatory approval status, label population, dosing guidance and any local post-marketing requirements.
- Takeda manufacturing capacity and India-specific supply allocation for the 2027 launch window.
- National Technical Advisory Group on Immunization and state-government recommendations on dengue vaccination.
- Private-market pricing, insurer coverage and employer or hospital vaccination-program participation.
- Dengue case trends, severity, geographic concentration and outbreak-driven procurement activity.
- Competitor dengue vaccine developments, local manufacturing announcements and alternative prevention interventions.
- Evidence on two-dose completion rates, physician acceptance and safety perceptions after commercial introduction.
- Build dengue-focused medical education for pediatricians, internists, infectious-disease specialists and hospital networks ahead of launch.
- Secure cold-chain, inventory-planning and two-dose patient-follow-up capabilities across priority high-incidence states.
- Pursue inclusion discussions with state health authorities, insurers, employers and large hospital chains to reduce out-of-pocket barriers.
- Use the Takeda relationship to seek additional vaccine or specialty-product distribution mandates.
- Position Qdenga within a broader seasonal dengue-awareness and diagnostics-referral ecosystem, subject to promotional and regulatory rules.